Skip to main content
. Author manuscript; available in PMC: 2024 Feb 16.
Published in final edited form as: Clin Imaging. 2020 Oct 13;70:18–24. doi: 10.1016/j.clinimag.2020.10.021

Table 2.

Characterization of additional malignancy detected on MRI.

Additional malignancies (n = 50)
Tumor subtype
 DCIS 28 (56%)
 IDC 18 (36%)
 ILC 4 (8%)
Tumor side
 Ipsilateral 37 (74%)
 Contralateral 13 (26%)
MRI finding
 Mass 37 (74%)
 Non-mass enhancement 13 (26%)
Histological diagnosis
 MR guided biopsy 23 (46%)
 US guided biopsy 12 (24%)
 Localization for excision 7 (14%)
 Mastectomy 8 (16%)